» Articles » PMID: 33385265

Patterns of Treatment and Outcome of Ductal Carcinoma in Situ in the Netherlands

Overview
Specialty Oncology
Date 2021 Jan 1
PMID 33385265
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To spare DCIS patients from overtreatment, treatment de-escalated over the years. This study evaluates the influence of these developments on the patterns of care in the treatment of DCIS with particular interest in the use of breast conserving surgery (BCS), radiotherapy following BCS and the use and type of axillary staging.

Methods: In this large population-based cohort study all women, aged 50-74 years diagnosed with DCIS from January 1989 until January 2019, were analyzed per two-year cohort.

Results: A total of 30,417 women were diagnosed with DCIS. The proportion of patients undergoing BCS increased from 47.7% in 1995-1996 to 72.7% in 2017-2018 (p < 0.001). Adjuvant radiotherapy following BCS increased from 28.9% (1995-1996) to 89.6% (2011-2012) and subsequently decreased to 74.9% (2017-2018; p < 0.001). Since its introduction, the use of sentinel lymph node biopsy (SLNB) increased to 63.1% in 2013-2014 and subsequently decreased to 52.8% in 2017-2018 (p < 0.001). Axillary surgery is already omitted in 55.8% of the patients undergoing BCS nowadays. The five-year invasive relapse-free survival (iRFS) for BCS with adjuvant radiotherapy in the period 1989-2010, was 98.7% [CI 98.4% - 99.0%], compared to 95.0% [CI 94.1% -95.8%] for BCS only (p < 0.001). In 2011-2018, this was 99.3% [CI 99.1% - 99.5%] and 98.8% [CI 98.2% - 99.4%] respectively (p = 0.01).

Conclusions: This study shows a shift toward less extensive treatment. DCIS is increasingly treated with BCS and less often followed by additional radiotherapy. The absence of radiotherapy still results in excellent iRFS. Axillary surgery is increasingly omitted in DCIS patients.

Citing Articles

Incidence trends of ductal carcinoma in situ in New Zealand women between 1999 and 2022.

Chen Q, Elwood M, Campbell I, Cavadino A, Aye P, Tin Tin S Breast Cancer Res Treat. 2025; .

PMID: 39856462 DOI: 10.1007/s10549-024-07582-6.


Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.

OLeary R, Duijm L, Boersma L, van der Sangen M, de Munck L, Wesseling J Br J Cancer. 2024; 131(5):852-859.

PMID: 38982194 PMC: 11369187. DOI: 10.1038/s41416-024-02785-6.


Adherence to guideline recommendations for follow-up in patients with DCIS at a large teaching hospital in the Netherlands.

Rajan K, Nijveldt J, Verheijen S, Siesling S, Beek M, Francken A Breast Cancer Res Treat. 2024; 207(3):633-640.

PMID: 38874687 DOI: 10.1007/s10549-024-07391-x.


Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery.

Kim Y, Ganduglia-Cazaban C, Tamirisa N, Lucci A, Krause T Ann Surg Oncol. 2024; 31(6):3649-3660.

PMID: 38319511 PMC: 11076367. DOI: 10.1245/s10434-024-14902-z.


The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.

Alaeikhanehshir S, Schmitz R, van den Belt-Dusebout A, van Duijnhoven F, Verschuur E, van Seijen M Breast Cancer Res Treat. 2023; 204(1):61-68.

PMID: 37964135 PMC: 10806034. DOI: 10.1007/s10549-023-07168-8.

References
1.
Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson L, Sandelin K . Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008; 26(8):1247-52. DOI: 10.1200/JCO.2007.12.7969. View

2.
Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett J, Brookes C . Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015; 51(16):2296-303. DOI: 10.1016/j.ejca.2015.07.017. View

3.
Bleyer A, Welch H . Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012; 367(21):1998-2005. DOI: 10.1056/NEJMoa1206809. View

4.
Rakovitch E, Pignol J, Chartier C, Hanna W, Kahn H, Wong J . The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2006; 101(3):335-47. DOI: 10.1007/s10549-006-9302-0. View

5.
Taylor C, Correa C, Duane F, Aznar M, Anderson S, Bergh J . Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017; 35(15):1641-1649. PMC: 5548226. DOI: 10.1200/JCO.2016.72.0722. View